^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
F182112
i
Other names: F182112
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Lunan Pharma
Drug class:
CD3 agonist, BCMA inhibitor
Related drugs:
over1year
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. (PubMed, J Hematol Oncol)
Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment of MM from the ASCO 2023 Annual Meeting.
Journal
|
Elrexfio (elranatamab-bcmm) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • F182112 • cevostamab (RG6160) • linvoseltamab (REGN5458)
Share via
